Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Erenumab Moves Ahead In Treatment-Refractory Migraine in Novartis/Amgen LIBERTY Study

Executive Summary

Top-line results from the Phase IIIb LIBERTY study are positive regarding primary and secondary endpoints, and could put erenumab ahead of other CGRP antagonists in difficult-to-treat migraine, as this novel class of agents nears the market for migraine prevention.

Advertisement

Related Content

Amgen's Aimovig Aims To Capture As Many Migraine Patients As Possible With $6,900 Price
Pharma Q1 Results Preview: Lilly, Biogen, Amgen, GSK & Roche
Deal Watch: Ionis Turns To Affiliate Akcea In Amyloidosis
10 First Approvals To Look Out For In 2018
Amgen Invests In Deals, Share Buybacks And Manufacturing As Sales Dip
Novartis Floats 'Bold' Value-Based Reimbursement Idea In Migraine

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100252

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel